How can I convert an oral estradiol 0.5 mg tablet to an equivalent compounded estradiol troche?

Converting Oral Estradiol 0.5 mg to Compounded Estradiol Troche

Do not convert oral estradiol 0.5 mg tablets to compounded estradiol troches—the Endocrine Society explicitly recommends against using custom-compounded hormones and advises using only FDA-approved preparations instead. 1

Why Compounded Troches Are Not Recommended

The 2015 Endocrine Society Clinical Practice Guideline provides an ungraded best practice statement that clearly states: "We recommend using MHT preparations approved by the FDA and comparable regulating bodies outside the United States and recommend against the use of custom-compounded hormones." 1 This recommendation exists because:

• FDA-approved preparations are already "biochemically identical" to endogenous estradiol and are preferred over custom-compounded options
• Custom-compounded hormone therapies lack standardized manufacturing controls, quality assurance, and consistent bioavailability data
• There is insufficient pharmacokinetic data to guide appropriate dosing conversions between formulations

The Pharmacokinetic Problem

Even if you were to attempt this conversion, the available evidence demonstrates significant challenges:

Compounded preparations show unpredictable absorption patterns. A 2013 randomized trial comparing compounded estrogen creams to conventional patches found that compounded preparations consistently yielded lower estrogen levels than expected, with the difference being statistically significant (AUC-estradiol for compounded 2.0mg = 181 vs. patch 956; p<0.001) 2. The study concluded that "to find comparable doses, further studies are needed."

Transbuccal/troche absorption differs fundamentally from oral absorption. A 2003 study of estradiol troches (0.5 mg) showed that hormones are "readily absorbed via the buccal mucous membrane" but provided no direct comparison to oral tablet bioequivalence 3. Without head-to-head bioequivalence data, any dose conversion would be speculative.

What You Should Do Instead

Continue with FDA-approved oral estradiol 0.5 mg tablets 4, which contain micronized estradiol and have well-established pharmacokinetics 5. If the oral route is problematic for your patient, consider these FDA-approved alternatives:

Alternative FDA-Approved Routes (in order of preference):

1. Transdermal estradiol patches (25-50 µg/day) - These avoid first-pass hepatic metabolism and are preferable for patients with VTE risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or gallbladder disease 1

2. Transdermal estradiol gels or sprays - Similar efficacy to oral preparations with the same advantages as patches 1

3. Vaginal estradiol rings (50-100 µg daily for systemic delivery) - Provide consistent systemic levels for 3 months 1

Dosing Principle

The Endocrine Society emphasizes using "the lowest effective dose with upward titration based on clinical response" 1. Estradiol levels are typically not measured to monitor therapy except when symptoms don't improve with escalating doses, particularly after changing administration routes 1.

Critical Caveat

If a patient specifically requests compounded hormones due to cost, access issues, or perceived benefits, this represents a shared decision-making opportunity. However, you must clearly document that you've counseled against compounded preparations per guideline recommendations, explained the lack of quality control and bioequivalence data, and that FDA-approved alternatives exist 1.